Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Winship Cancer Institute, Emory University
Atlanta, Georgia, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Mt. Sinai Medical Center
New York, New York, United States
- University of Pennsylvania
Philadelphia, Pennsylvania, United States
- Md Anderson Cancer Center
Houston, Texas, United States
- Medical College of Wisconsin - Clinical Cancer Center
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2011
- Primary completion
- 31 Dec 2016
- Completion
- 3 Dec 2016
- Last update posted
- 6 Apr 2017
- Registered enrollment
- 120
- Registry id
- NCT01323751
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.